BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31482428)

  • 1. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinoma.
    Frood R; Mercer J; Brown P; Appelt A; Mistry H; Kochhar R; Scarsbrook A
    Eur Radiol; 2024 May; 34(5):3194-3204. PubMed ID: 37924344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
    Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
    Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma.
    Duimering A; Riauka T; Nijjar Y; Ghosh S; MacEwan R; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Nijjar T; Fairchild A; Mulder K; Doll C; Wong C; Joseph K
    Radiother Oncol; 2019 Jul; 136():21-28. PubMed ID: 31015125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-based FDG PET-CT radiomics for outcome prediction in larynx and hypopharynx squamous cell carcinoma.
    Zhong J; Frood R; Brown P; Nelstrop H; Prestwich R; McDermott G; Currie S; Vaidyanathan S; Scarsbrook AF
    Clin Radiol; 2021 Jan; 76(1):78.e9-78.e17. PubMed ID: 33036778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre- and post-treatment FDG PET-CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta-analysis.
    Mac Curtain BM; Qian W; Bell J; O'Mahony A; Temperly HC; Ng ZQ
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):634-646. PubMed ID: 37573606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers.
    Niyoteka S; Seban RD; Rouhi R; Scarsbrook A; Genestie C; Classe M; Carré A; Sun R; La Greca Saint-Esteven A; Chargari C; McKenna J; McDermott G; Malinen E; Tanadini-Lang S; Guckenberger M; Guren MG; Lemanski C; Deutsch E; Robert C
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4010-4023. PubMed ID: 37632562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
    Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anal cancer chemoradiotherapy outcome prediction using
    Rusten E; Rekstad BL; Undseth C; Klotz D; Hernes E; Guren MG; Malinen E
    Br J Radiol; 2019 May; 92(1097):20181006. PubMed ID: 30810343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
    Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
    Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 18F-FDG PET-derived parameters for predicting complete response to chemoradiotherapy in squamous cell anal carcinoma.
    Filippi L; Fontana A; Spinelli GP; Rossi L; Bagni O
    Nucl Med Commun; 2020 Oct; 41(10):1089-1094. PubMed ID: 32732599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomic feature analysis of pre-treatment FDG PET-CT for predicting outcome in anal squamous cell carcinoma.
    Li X; Xia Z; Li W
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2733-2734. PubMed ID: 32277248
    [No Abstract]   [Full Text] [Related]  

  • 13. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an [
    Takahashi N; Tanaka S; Umezawa R; Takanami K; Takeda K; Yamamoto T; Suzuki Y; Katsuta Y; Kadoya N; Jingu K
    Acta Oncol; 2023 Feb; 62(2):159-165. PubMed ID: 36794365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of
    Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
    J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
    Mayerhoefer ME; Riedl CC; Kumar A; Gibbs P; Weber M; Tal I; Schilksy J; Schöder H
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2760-2769. PubMed ID: 31286200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of [
    Li K; Sun H; Lu Z; Xin J; Zhang L; Guo Y; Guo Q
    Eur J Radiol; 2018 Sep; 106():160-166. PubMed ID: 30150039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
    Jones MP; Hruby G; Metser U; Sridharan S; Capp A; Kumar M; Gallagher S; Rutherford N; Holder C; Oldmeadow C; Martin J
    Radiat Oncol; 2019 Aug; 14(1):140. PubMed ID: 31387597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.